Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study

Dalfampridine extended release tablets (D-ER; prolonged-release fampridine in Europe) are available to improve walking in patients with multiple sclerosis (MS). D-ER is mainly renally eliminated; the approved 10-mg twice daily dose is contraindicated in the United States in patients with moderate or...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Pharmacol
Autors principals: Samara, Emil, Winkle, Peter, Pardo, Patricia, Henney, Herbert R, Way, Susan L, Brown, Eppie, Lee, Angela, Blight, Andrew R
Format: Artigo
Idioma:Inglês
Publicat: BlackWell Publishing Ltd 2014
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4263161/
https://ncbi.nlm.nih.gov/pubmed/24150835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.189
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars